Highbridge Capital Management LLC Invests $1.48 Million in BioAtla, Inc. (NASDAQ:BCAB)

Highbridge Capital Management LLC bought a new stake in BioAtla, Inc. (NASDAQ:BCAB) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,509,626 shares of the company’s stock, valued at approximately $1,484,000. Highbridge Capital Management LLC owned approximately 5.19% of BioAtla at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. Magnus Financial Group LLC acquired a new position in BioAtla in the fourth quarter valued at $28,000. XTX Topco Ltd lifted its holdings in shares of BioAtla by 7.2% in the 3rd quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock valued at $273,000 after purchasing an additional 10,384 shares during the last quarter. Norges Bank purchased a new stake in shares of BioAtla in the 4th quarter valued at about $230,000. Finally, Massachusetts Financial Services Co. MA boosted its position in shares of BioAtla by 5.2% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 569,332 shares of the company’s stock valued at $1,002,000 after purchasing an additional 28,133 shares during the period. 77.23% of the stock is owned by hedge funds and other institutional investors.

BioAtla Stock Up 4.8 %

BCAB opened at $0.39 on Friday. BioAtla, Inc. has a 52 week low of $0.24 and a 52 week high of $4.02. The business’s 50 day moving average is $0.41 and its two-hundred day moving average is $1.14. The firm has a market cap of $18.98 million, a price-to-earnings ratio of -0.23 and a beta of 1.19.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.